The Science Is Working. The CMC Isn’t Always Keeping Up.
For years, pharmaceutical and biotechnology companies viewed clinical development as the primary hurdle to product approval.
If the clinical data were compelling, approval seemed inevitable.
Today’s regulatory environment tells a different story.
Increasingly, innovative therapies are reaching the FDA finish line only to receive a Complete Response Letter (CRL). While every CRL is unique, one trend has become increasingly clear:
Many approval delays are not being driven by clinical efficacy or safety concerns. They are being driven by Chemistry, Manufacturing, and Controls (CMC) – 75%...
As therapies become more complex and manufacturing networks more global, regulators are placing unprecedented scrutiny on manufacturing readiness, process robustness, data integrity, facility compliance, and commercial scalability.
The result is a growing number of programs finding themselves unexpectedly delayed despite years of successful clinical development.
Why FDA Scrutiny Is Increasing
The FDA faces enormous pressure to ensure that innovative therapies reaching patients can be manufactured consistently, safely, and reliably.
A promising molecule alone is no longer enough.
The agency increasingly expects sponsors to demonstrate:
Process understanding
Manufacturing control
Commercial readiness
Data integrity
Supply chain robustness
Facility compliance
Inspection readiness
Product lifecycle sustainability
In short, FDA wants confidence that companies can consistently manufacture the product after approval—not just produce material for clinical trials.
This shift is particularly evident in:
Cell and Gene Therapies
Biologics
Advanced Therapies
Sterile Injectable Products
Complex Generics
Novel Manufacturing Platforms
Many organizations underestimate how different commercial manufacturing expectations are from clinical manufacturing expectations.
Common CMC Issues Behind CRLs
Although specific details vary, many recent CRLs have involved concerns related to:
Manufacturing Facility Readiness
FDA inspections frequently identify issues that call into question operational maturity and quality oversight.
Common observations include:
Inadequate quality systems
Weak deviation management
Incomplete CAPA effectiveness
Data integrity concerns
Poor documentation practices
Process Validation and Control
FDA expects manufacturers to demonstrate that processes are understood, controlled, and capable of producing consistent product quality.
Common gaps include:
Insufficient process characterization
Inadequate PPQ strategies
Limited lifecycle management plans
Weak control strategies
Sterility Assurance and Contamination Control
Particularly for sterile products and advanced therapies, FDA scrutiny continues to increase.
Areas of focus include:
Environmental monitoring
Aseptic processing practices
Human factors
Contamination Control Strategy (CCS)
Media fill execution
Cleanroom behaviors
Analytical and Data Integrity Concerns
Questions regarding data reliability can quickly undermine confidence in an entire submission.
Areas frequently reviewed include:
Audit trails
Laboratory controls
Method validation
Data governance
Computerized systems
Commercialization Readiness
Many companies successfully navigate development but struggle during the transition to commercial manufacturing.
The FDA increasingly evaluates whether organizations possess:
Scalable manufacturing capabilities
Robust quality oversight
Sustainable supply chains
Commercial operational maturity
Why These Challenges Are Increasing
The reality is that most emerging biopharmaceutical companies were built around science.
They were not built around manufacturing.
As organizations advance through clinical development, they often discover that their internal expertise does not fully align with the demands of commercialization.
This creates significant risk during:
Pre-BLA preparation
Facility inspections
Tech transfer
Process validation
Commercial launch readiness
By the time FDA identifies the gaps, the cost of remediation can be measured in months—or even years.
The Cost of a CRL
The financial impact of a CRL extends far beyond delayed revenue.
Organizations often face:
Market value declines
Delayed patient access
Increased operational costs
Additional studies
Manufacturing remediation expenses
Investor concerns
Competitive disadvantages
Most importantly, valuable time is lost.
In today’s competitive environment, approval delays can dramatically alter the commercial trajectory of a product.
How QxP Helps Organizations Reduce Approval Risk
At Quality Executive Partners (QxP), we help organizations identify and address CMC vulnerabilities before they become regulatory obstacles.
Our approach combines strategic expertise with practical execution.
CMC Readiness Assessments
We evaluate programs against FDA expectations and identify potential approval risks before submission.
Inspection Readiness
Our experts prepare organizations for regulatory inspections through realistic assessments, mock inspections, and leadership coaching.
Quality System Maturity
We help organizations strengthen:
Quality Management Systems
Deviation Programs
CAPA Systems
Change Management
Data Governance
Sterility Assurance and Contamination Control
QxP’s sterility experts support:
Contamination Control Strategy development
Aseptic process optimization
Media fill oversight
Annex 1 readiness
Human factors improvement
Tech Transfer and Commercialization Support
We help organizations successfully transition from clinical to commercial operations through:
Process transfer governance
Validation strategy
Operational readiness assessments
Supply chain risk mitigation
Regulatory Recovery
For organizations facing regulatory challenges, warning letters, inspection findings, or CRLs, QxP provides experienced leadership to accelerate recovery and rebuild agency confidence.
The New Reality: Approval Requires More Than Good Science
The pharmaceutical industry is entering an era where manufacturing excellence is becoming just as important as clinical success.
The companies that succeed will be those that recognize CMC not as a late-stage requirement, but as a strategic enabler of approval.
The FDA’s increasing scrutiny is unlikely to diminish.
If anything, expectations will continue to rise.
Organizations that invest early in quality systems, operational maturity, manufacturing readiness, and regulatory preparedness will be best positioned to bring therapies to patients without unnecessary delays.
“The science may get you to the finish line. CMC determines whether you cross it and if so, when.”
About Quality Executive Partners
QxP helps pharmaceutical and biotechnology organizations accelerate commercialization, strengthen quality systems, prepare for inspections, recover from regulatory challenges, and reduce approval risk through experienced industry leaders in quality, regulatory affairs, sterility assurance, CMC, and operational excellence.
Don’t wait for a CRL to discover your vulnerabilities. Find them before FDA does.
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
